Pebble hires MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer

DALLAS–(BUSINESS WIRE)–Pebble Global Holdings (aka “Pebble Life Sciences” or “Pebble”), a private, Texas-based leader in non-psychotropic cannabinoid research for drug development, today announced that a research program sponsored entitled “Evaluation of multi-cannabinoid formulations in ovarian cancerwas launched in 2020 and currently exists between Pebble and MD Anderson Cancer Center (“MD Anderson”). MD Anderson is one of the world’s most respected centers dedicated exclusively to cancer patient care, education, prevention, research and ranked #1 in cancer in the world. US news and world reportAnnual “Best Hospitals” 2021-2022.

Although it is one of the most studied, ovarian cancer is the leading cause of gynecological cancer in the United States and the second in the world. It is the fifth leading cause of cancer death in American women, with 22,000 diagnoses in 2021 resulting in 14,000 deaths. 75% of patients are “advanced” at the time of initial diagnosis, with 1 in 6 dying within 90 days and treatment being limited by severe adverse effects to the current standard of care.

“Our team has thoroughly enjoyed working with MD Anderson over the past two years on this new therapy. We are delighted to continue with MD Anderson, to improve the standards of care in cancer treatment. Pebble’s non-THC, non-psychotropic approach enables a drug regulatory pathway that enables national and global distribution, so we can help as many suffering women as possible,” says Patrick Moran, Founder and CEO of Pebble.

About Pebble Life Sciences

Pebble is the cannabinoid-focused subsidiary of AcquiFlow LLC (founded in 2014 as the first Texas-based “open, legal and transparent” cannabis company; whose holdings include a patent area in the genetics of non-consumable industrial hemp ). Pebble has established a patent heritage sufficient to help fuel the marketing, sales and distribution channels of a large cap company. These filings protect both the process of formulating Pebble’s cannabinoid compounds and the successful initial prototype. Pebble OTC versions of products are available for purchase at, maintain pharmaceutical variance standards and provide independent third-party testing for every batch.

About the MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center (colloquially MD Anderson Cancer Center) is a comprehensive cancer center in Houston, Texas. It is the largest cancer center in the United States and one of the top three comprehensive cancer centers in the country. It is both a degree-granting academic institution and a cancer treatment and research center located at the Texas Medical Center in Houston. It is affiliated with the University of Texas Health Sciences Center at Houston.

Comments are closed.